Previous 10 | Next 10 |
2023-04-03 10:02:08 ET Gainers: Heska ( HSKA ) +20% . Heron Therapeutics ( HRTX ) +19% . InterCure ( INCR ) +17% . Innate Pharma ( IPHA ) +15% . Apellis Pharmaceuticals ( APLS ) +14% . Losers: OncoSec Medical ( ONCS...
2023-04-03 07:35:28 ET Annovis Bio press release ( NYSE: ANVS ): Q4 net loss of $7.7M. Cash and cash equivalents were $28.4 million as of December 31, 2022. For further details see: Annovis Bio reports Q4 results
ANNOVIS BIO ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE PR Newswire BERWYN, Pa. , April 3, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company...
2023-03-30 12:00:30 ET Summary Lead asset buntanetap represents a differentiated, potentially disease-modifying mechanism of action in neurodegenerative diseases. Interim Phase 3 Parkinson's data to be presented today (3/30/23) at AD/PD 2023 conference. Micro-cap status ($180 ...
2023-03-29 15:46:29 ET Shares of Alzheimer's drug developer Annovis Bio ( NYSE: ANVS ) rose ~17% Wednesday to the highest level since November 2021 as the company was scheduled to make a presentation disclosing late-stage data for its lead candidate buntanetap. Previou...
ANNOVIS BIO ANNOUNCES TWO PRESENTATIONS AT THE AD/PD™ 2023 INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASES PR Newswire BERWYN, Pa. , March 22, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clin...
Annovis Bio ( NYSE: ANVS ) announced Wednesday the EU approval to bring additional 48 trial sites for its Phase 3 study for lead candidate buntanetap in the treatment of Parkinson's disease ("PD"). With 50 clinical trial sites open in the U.S., the clinical-stage biotech is currently ...
Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease PR Newswire The Company was Granted Approval for an Additional 48 sites Across Five European Union Countries Annovis Currently ...
Summary The treatment of Moderate Alzheimer's disease requires intervention after the over-activation of NMDA receptors. BioVie does this by reducing the phosphorlyation of ERK (Extracellular Regulatory Kinase) and by inhibiting NF-kB (Nuclear Factor-kappa Beta). Panax ginseng does ...
Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses PR Newswire BERWYN, Pa. , Feb. 1, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clin...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYS...